search
Back to results

Anti-malaria MAb in Kenyan Children

Primary Purpose

Plasmodium Falciparum Infection, Malaria

Status
Recruiting
Phase
Phase 2
Locations
Kenya
Study Type
Interventional
Intervention
L9LS
Normal Saline
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Plasmodium Falciparum Infection focused on measuring monoclonal, antibody, Kenya, malaria, children

Eligibility Criteria

5 Months - 10 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy children aged 5 months to 10 years (Part 1) or 5-59 months (Part 2).
  2. Weight ≥5 kg and weight ≤30 kg (Part 1) or weight ≥5 kg and ≤22.5 kg (Part 2).
  3. Hemoglobin level ≥8 g/dL.
  4. Height and weight Z-scores >-2.
  5. Living within Alego-Usonga sub-county.
  6. Able to participate for the duration of the trial.
  7. Parent and/or guardian of participant able to provide informed consent.

Exclusion Criteria:

  1. Taking long-term cotrimoxazole.
  2. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit or receipt of an investigational product within the past 30 days. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.)
  3. Received any doses of any malaria vaccine.
  4. Participation in part 1 of this study (for individuals being screened for enrollment into part 2)
  5. Age < 12 months at the time the RTS,S/AS01 vaccine is anticipated to become available in the whole of Siaya County
  6. Current significant medical condition (neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, authoimmune, renal, oncologic, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination.

    1. Known sickle cell disease. (Note: Known sickle cell trait is NOT exclusionary.)
    2. Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
    3. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
    4. Infected with HIV.
    5. History of a severe allergic reaction or anaphylaxis.
    6. Severe asthma (defined as asthma that is unstable or required emergency care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
    7. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia.
    8. Known immunodeficiency syndrome.
    9. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of day 0.
    10. Known asplenia or functional asplenia.
    11. Clinical signs of malnutrition.
    12. Receipt of immunoglobulins and/or blood products within the past 6 months.
  7. Any history of menses.
  8. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol.
  9. Parental/guardian study comprehension examination score of <80% correct or per investigator discretion.
  10. Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.
  11. Known allergies or contraindication to dihydroartemisinin-piperaquine.
  12. Use or known need at the time of enrolment (DP administration) for concomitant prohibited medication. Patients taking any of the following drugs:

    a. Antimicrobial agents of the following classes (systemic use only): i. Macrolides (e.g. erythromycin, clarithromycin, azithromycin, roxithromycin) ii. Fluoroquinolones (e.g., levofloxacin, moxifloxacin, sparfloxacin) iii. Pentamidine b. Antiarrhythmic agents (e.g. amiodarone, sotalol) c. Antihistamines (e.g. promethazine) d. Antifungals (systemic): ketoconazole, fluconazole, itraconazole e. Antiretrovirals: Saquinavir f. Diuretics (e.g. hydrochlorothiazide, furosemide) g. Antipsychotics (neuroleptics): haloperidol, thioridazine h. Antidepressants: imipramin, citalopram, escitalopram i. Antiemetics: domperidone, chlorpromazine, ondansetron

  13. Increased risk of salivary gland hypofunction (dryness of the mouth, swelling under the tongue and/or below the ear, halitosis)
  14. History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives, or other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or render the subject unable to comply with the protocol.

Sites / Locations

  • Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm Type

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Placebo Comparator

Arm Label

Part 1: Children age 5-10: 5 mg/kg of L9LS

Part 1: Children age 5-10: Placebo

Part 1: Children age 5-59 months: 5 mg/kg of L9LS

Part 1: Children age 5-10 years: 10 mg/kg of L9LS

Part 1: Children age 5-10 years: 20 mg/kg of L9LS

Part 1: Children age 5-59 months: 10 mg/kg of L9LS

Part 1: Children age 5-59 months: 20 mg/kg of L9LS

Part 1: Children age 5-59 months: Placebo

Part 2: Children age 5-17 months: 1 dose L9LS at 10-19 mg/kg

Part 2: Children age 5-17 months: 2 doses L9LS at 10-19 mg/kg

Part 2: Children age 5-17 months: Placebo

Part 2: Children age 18-59 months: 1 dose L9LS at 10-19 mg/kg

Part 2: Children age 18-59 months: 2 doses L9LS at 10-19 mg/kg

Part 2: Children age 18-59 months: Placebo

Arm Description

Enrolled individuals will receive 5 mg/kg of L9LS via SC injection.

1/4 of children age 5-10 will receive placebo of Normal Saline for comparison.

1/4 of subjects age 5-59 months will receive placebo of Normal Saline for comparison.

Subjects age 5-17 months will receive 1 dose of L9LS via SC injection.

Subjects age 5-17 months will receive 1 dose of L9LS and a second dose at 6 months via SC injection.

1/3 of subjects age 5-17 months will receive placebo of normal saline for comparison.

Subjects age 18-59 months will receive 1 dose L9LS via SC injection.

Subjects age 18-59 months will receive 1 dose L9LS, followed by a second dose at 6 months via SC injection.

1/3 of subjects age 18-59 months will receive placebo of normal saline for comparison.

Outcomes

Primary Outcome Measures

Incidence and severity of local and systemic adverse events (AEs) occurring within 7 days after the administration of L9LS.
Age de-escalation and dose-escalation study
Incidence and severity of local and systemic adverse events (AEs) occurring within 7 days after the administration of L9LS.
Efficacy study
Rate of Pf blood-stage infection in participants as detected by microscopic examination of thick blood smear for 52 weeks after administration of two doses of L9LS or placebo.
Efficacy study

Secondary Outcome Measures

Rate of Pf blood-stage infection in participants as detected by microscopic examination of thick blood smear after administration of one dose of L9LS or placebo.
Efficacy study
Pf blood-stage infection as detected by microscopic examination of thick blood smear diagnosed by blood smear microscopy after administration of one dose of L9LS or placebo.
Efficacy study
Rate of Pf blood-stage infection in participants as detected by RT-PCR of L9LS or placebo.
Efficacy study
Incidence of clinical malaria: an illness accompanied by measured fever ≥37.5°C in the previous 24 hours and Pf asexual parasitemia >5,000 parasites/μL as detected from microscopic examination of thick blood smear.
Age de-escalation, dose-escalation and efficacy study
Incidence of clinical malaria: fever ≥37.5°C, history of fever in the previous 24 hours accompanied by any level of Pf asexual parasitemia, detected from microscopic examination of thick blood smear, requires administration of anti-malarial treatment.
Age de-escalation, dose-escalation and efficacy study
L9LS sera concentration
Age de-escalation, dose-escalation and efficacy study

Full Information

First Posted
May 12, 2022
Last Updated
September 15, 2022
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Centers for Disease Control and Prevention, National Institutes of Health (NIH), Vaccine Research Center (VRC), Kenya Medical Research Institute, Liverpool School of Tropical Medicine (LSTM)
search

1. Study Identification

Unique Protocol Identification Number
NCT05400655
Brief Title
Anti-malaria MAb in Kenyan Children
Official Title
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2022 (Actual)
Primary Completion Date
March 15, 2024 (Anticipated)
Study Completion Date
April 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Centers for Disease Control and Prevention, National Institutes of Health (NIH), Vaccine Research Center (VRC), Kenya Medical Research Institute, Liverpool School of Tropical Medicine (LSTM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective efficacy of one or two doses of L9LS against naturally occurring Plasmodium falciparum (Pf) infection among Kenyan children aged 5 to 59 months at enrollment, in a setting of perennial high transmission.
Detailed Description
A two-part, phase 2 trial evaluating the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective efficacy of one or two doses of L9LS against naturally occurring Plasmodium falciparum (Pf) infection among Kenyan children aged 5 to 59 months at enrollment, in a setting of perennial high transmission. Part 1 is an age de-escalation and dose-escalation study. In a stepwise fashion, children aged 5-10 years will receive 5 mg/kg of L9LS or placebo and be followed for 3 months to assess tolerability and safety. If acceptable tolerability and safety profiles are met at 1-week post-injection, the 5 mg/kg dose of L9LS or placebo will be administered to children aged 5-59 months while enrolling another cohort of children aged 5-10 years at a dose of 10 mg/kg of L9LS or placebo. If after 1 week, the 10 mg/kg dose is found to be safe in children aged 5-10 years and the 5 mg/kg dose is found to be safe in children aged 5-59 months, a 20 mg/kg dose of L9LS or placebo will be administered to children aged 5-10 years and a 10 mg/kg dose of L9LS or placebo to children aged 5-59 months. Finally, if these doses are found safe after 1 week, a 20 mg/kg dose of L9LS or placebo will be administered to children aged 5-59 months. Should tolerability and safety of all doses be acceptable in children aged 5-59 months, part 2 of the trial will begin. Dosing in part 1 of the study will be weight-based and all doses will be administered SC in a double-blinded fashion. 12 participants in each age-dose group will be enrolled in a 3:1 ratio of L9LS to placebo, and all participants will be followed for a total of 3 months. Part 2 is the efficacy study. Children 5-59 months of age will be randomized to receive a 10-19 mg/kg dose of L9LS or placebo by SC administration. There will be two L9LS cohorts, one 5-17 months of age and another 18-59 months of age, which will constitute one L9LS arm. A placebo arm will be composed of children 5-59 months of age. They will be followed over 12 months with monthly blood smear microscopy and polymerase chain reaction (PCR) and twice-monthly symptomatology and careseeking behavior questionnaires. Dosing will be based on three weight bands; all doses will be administered SC with fixed doses of 75 mg L9LS, 150 mg L9LS, or 225 Mg L9LS, resulting in a range of 10-19 mg/kg in a double-blinded fashion. Blood will be drawn to assess antibody titers at baseline, and at three additional time points over 12 months to establish pharmacokinetics (PK). Participants in the L9LS arm will be randomized 1:1 at baseline to receive either a second L9LS injection or a placebo injection to evaluate the additional efficacy of a second dose administered 6 months after the first dose. (Those in the placebo arm will receive a second injection of placebo.) Participants will be followed for an additional 6 months after the second injection with monthly blood smear microscopy and PCR, and a blood draw at month 11 to assess L9LS PK.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plasmodium Falciparum Infection, Malaria
Keywords
monoclonal, antibody, Kenya, malaria, children

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
720 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Children age 5-10: 5 mg/kg of L9LS
Arm Type
Experimental
Arm Description
Enrolled individuals will receive 5 mg/kg of L9LS via SC injection.
Arm Title
Part 1: Children age 5-10: Placebo
Arm Type
Placebo Comparator
Arm Description
1/4 of children age 5-10 will receive placebo of Normal Saline for comparison.
Arm Title
Part 1: Children age 5-59 months: 5 mg/kg of L9LS
Arm Type
Experimental
Arm Title
Part 1: Children age 5-10 years: 10 mg/kg of L9LS
Arm Type
Experimental
Arm Title
Part 1: Children age 5-10 years: 20 mg/kg of L9LS
Arm Type
Experimental
Arm Title
Part 1: Children age 5-59 months: 10 mg/kg of L9LS
Arm Type
Experimental
Arm Title
Part 1: Children age 5-59 months: 20 mg/kg of L9LS
Arm Type
Experimental
Arm Title
Part 1: Children age 5-59 months: Placebo
Arm Type
Placebo Comparator
Arm Description
1/4 of subjects age 5-59 months will receive placebo of Normal Saline for comparison.
Arm Title
Part 2: Children age 5-17 months: 1 dose L9LS at 10-19 mg/kg
Arm Type
Experimental
Arm Description
Subjects age 5-17 months will receive 1 dose of L9LS via SC injection.
Arm Title
Part 2: Children age 5-17 months: 2 doses L9LS at 10-19 mg/kg
Arm Type
Experimental
Arm Description
Subjects age 5-17 months will receive 1 dose of L9LS and a second dose at 6 months via SC injection.
Arm Title
Part 2: Children age 5-17 months: Placebo
Arm Type
Placebo Comparator
Arm Description
1/3 of subjects age 5-17 months will receive placebo of normal saline for comparison.
Arm Title
Part 2: Children age 18-59 months: 1 dose L9LS at 10-19 mg/kg
Arm Type
Experimental
Arm Description
Subjects age 18-59 months will receive 1 dose L9LS via SC injection.
Arm Title
Part 2: Children age 18-59 months: 2 doses L9LS at 10-19 mg/kg
Arm Type
Experimental
Arm Description
Subjects age 18-59 months will receive 1 dose L9LS, followed by a second dose at 6 months via SC injection.
Arm Title
Part 2: Children age 18-59 months: Placebo
Arm Type
Placebo Comparator
Arm Description
1/3 of subjects age 18-59 months will receive placebo of normal saline for comparison.
Intervention Type
Drug
Intervention Name(s)
L9LS
Intervention Description
Administered subcutaneously.
Intervention Type
Other
Intervention Name(s)
Normal Saline
Intervention Description
Administered subcutaneously.
Primary Outcome Measure Information:
Title
Incidence and severity of local and systemic adverse events (AEs) occurring within 7 days after the administration of L9LS.
Description
Age de-escalation and dose-escalation study
Time Frame
Measured through Day 7
Title
Incidence and severity of local and systemic adverse events (AEs) occurring within 7 days after the administration of L9LS.
Description
Efficacy study
Time Frame
Measured through Day 7
Title
Rate of Pf blood-stage infection in participants as detected by microscopic examination of thick blood smear for 52 weeks after administration of two doses of L9LS or placebo.
Description
Efficacy study
Time Frame
Measured through week 52
Secondary Outcome Measure Information:
Title
Rate of Pf blood-stage infection in participants as detected by microscopic examination of thick blood smear after administration of one dose of L9LS or placebo.
Description
Efficacy study
Time Frame
Measured through 12 and 24 weeks after drug or placebo administration
Title
Pf blood-stage infection as detected by microscopic examination of thick blood smear diagnosed by blood smear microscopy after administration of one dose of L9LS or placebo.
Description
Efficacy study
Time Frame
Measured for 52 weeks after drug or placebo administration
Title
Rate of Pf blood-stage infection in participants as detected by RT-PCR of L9LS or placebo.
Description
Efficacy study
Time Frame
Measured at 24 and 52 weeks after drug or placebo administration
Title
Incidence of clinical malaria: an illness accompanied by measured fever ≥37.5°C in the previous 24 hours and Pf asexual parasitemia >5,000 parasites/μL as detected from microscopic examination of thick blood smear.
Description
Age de-escalation, dose-escalation and efficacy study
Time Frame
Measured at 24 and 52 weeks after drug or placebo administration
Title
Incidence of clinical malaria: fever ≥37.5°C, history of fever in the previous 24 hours accompanied by any level of Pf asexual parasitemia, detected from microscopic examination of thick blood smear, requires administration of anti-malarial treatment.
Description
Age de-escalation, dose-escalation and efficacy study
Time Frame
Measured at 24 and 52 weeks after drug or placebo administration
Title
L9LS sera concentration
Description
Age de-escalation, dose-escalation and efficacy study
Time Frame
Through Day 336

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Months
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy children aged 5 months to 10 years (Part 1) or 5-59 months (Part 2). Weight ≥5 kg and weight ≤30 kg (Part 1) or weight ≥5 kg and ≤22.5 kg (Part 2). Hemoglobin level ≥8 g/dL. Height and weight Z-scores >-2. Living within Alego-Usonga sub-county. Able to participate for the duration of the trial. Parent and/or guardian of participant able to provide informed consent. Exclusion Criteria: Taking long-term cotrimoxazole. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit or receipt of an investigational product within the past 30 days. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.) Received any doses of any malaria vaccine. Participation in part 1 of this study (for individuals being screened for enrollment into part 2) Age < 12 months at the time the RTS,S/AS01 vaccine is anticipated to become available in the whole of Siaya County Current significant medical condition (neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, authoimmune, renal, oncologic, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination. Known sickle cell disease. (Note: Known sickle cell trait is NOT exclusionary.) Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.) Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.) Infected with HIV. History of a severe allergic reaction or anaphylaxis. Severe asthma (defined as asthma that is unstable or required emergency care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years). Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia. Known immunodeficiency syndrome. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of day 0. Known asplenia or functional asplenia. Clinical signs of malnutrition. Receipt of immunoglobulins and/or blood products within the past 6 months. Any history of menses. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol. Parental/guardian study comprehension examination score of <80% correct or per investigator discretion. Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration. Known allergies or contraindication to dihydroartemisinin-piperaquine. Use or known need at the time of enrolment (DP administration) for concomitant prohibited medication. Patients taking any of the following drugs: a. Antimicrobial agents of the following classes (systemic use only): i. Macrolides (e.g. erythromycin, clarithromycin, azithromycin, roxithromycin) ii. Fluoroquinolones (e.g., levofloxacin, moxifloxacin, sparfloxacin) iii. Pentamidine b. Antiarrhythmic agents (e.g. amiodarone, sotalol) c. Antihistamines (e.g. promethazine) d. Antifungals (systemic): ketoconazole, fluconazole, itraconazole e. Antiretrovirals: Saquinavir f. Diuretics (e.g. hydrochlorothiazide, furosemide) g. Antipsychotics (neuroleptics): haloperidol, thioridazine h. Antidepressants: imipramin, citalopram, escitalopram i. Antiemetics: domperidone, chlorpromazine, ondansetron Increased risk of salivary gland hypofunction (dryness of the mouth, swelling under the tongue and/or below the ear, halitosis) History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives, or other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or render the subject unable to comply with the protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Titus Kwambai, MD, PhD
Phone
254 722207281
Email
qbb5@cdc.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Steinhardt, PhD, MPH
Phone
255 677 680 008
Email
LSteinhardt@cdc.gov
Facility Information:
Facility Name
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR)
City
Kisumu
Country
Kenya
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Titus Kwambai, MD, PhD
Phone
254 722207281
Email
qbb5@cdc.gov

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Anti-malaria MAb in Kenyan Children

We'll reach out to this number within 24 hrs